Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Lyell Immunopharma (LYEL) Other Non Operating Income (2020 - 2025)

Lyell Immunopharma (LYEL) has disclosed Other Non Operating Income for 6 consecutive years, with -$15.8 million as the latest value for Q4 2025.

  • Quarterly Other Non Operating Income fell 467.08% to -$15.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$18.1 million through Dec 2025, down 486.11% year-over-year, with the annual reading at -$18.1 million for FY2025, 486.11% down from the prior year.
  • Other Non Operating Income hit -$15.8 million in Q4 2025 for Lyell Immunopharma, down from -$4.9 million in the prior quarter.
  • In the past five years, Other Non Operating Income ranged from a high of $4.3 million in Q4 2024 to a low of -$15.8 million in Q4 2025.
  • Historically, Other Non Operating Income has averaged -$492900.0 across 5 years, with a median of -$20500.0 in 2021.
  • Biggest five-year swings in Other Non Operating Income: skyrocketed 6768.18% in 2022 and later tumbled 11200.0% in 2025.
  • Year by year, Other Non Operating Income stood at -$44000.0 in 2021, then surged by 6768.18% to $2.9 million in 2022, then crashed by 117.25% to -$506000.0 in 2023, then surged by 948.22% to $4.3 million in 2024, then plummeted by 467.08% to -$15.8 million in 2025.
  • Business Quant data shows Other Non Operating Income for LYEL at -$15.8 million in Q4 2025, -$4.9 million in Q3 2025, and $1.2 million in Q2 2025.